




RealRate

PHARMACEUTICAL 2019

LIGAND PHARMACEUTICALS INC Rank 164 of 363





PHARMACEUTICAL 2019

LIGAND PHARMACEUTICALS INC
Rank 164 of 363



The relative strengths and weaknesses of LIGAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIGAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 68% points. The greatest weakness of LIGAND PHARMACEUTICALS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 76% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	870,540
Cost of Goods Sold	6,337
Intangible Assets	306,439
Liabilities, Current	82,249
Liabilities, Non-Current	951
Other Assets	78,452
Other Compr. Net Income	-848
Other Expenses	45,801
Other Liabilities	616,689
Other Net Income	9,603
Other Revenues	251,453
Property and Equipment	5,372
Research and Development	27,863
Selling, General and Administrative Expense	37,734

Output Variable	Value in 1000 USD
Assets	1,260,803
Liabilities	699,889
Expenses	117,735
Revenues	251,453
Stockholders Equity	560,914
Net Income	143,321
Comprehensive Net Income	142,897
Economic Capital Ratio	113%